Biovica International AB (publ)

SSE:BIOVIC-B.ST

2.34 (SEK) • At close February 20, 2024
Bedrijfsnaam Biovica International AB (publ)
Symbool BIOVIC-B.ST
Munteenheid SEK
Prijs 2.34
Beurswaarde 182,015,262
Dividendpercentage 0%
52-weken bereik 2.205 - 10.36
Industrie Biotechnology
Sector Healthcare
CEO Mr. Anders Rylander
Website https://www.biovica.com

An error occurred while fetching data.

Over Biovica International AB (publ)

Biovica International AB (publ), a biotechnology company, develops and commercializes blood-based biomarker assays that enhance the monitoring and predicting of cancer therapies in Sweden and internationally. It primarily focuses on breast cancer. The company develops DiviTum, a biomarker assay that measures the activity of the enzyme thymidine kinase-1 in blood

Vergelijkbare Aandelen

Paxman AB (publ) logo

Paxman AB (publ)

PAX.ST

38.6 SEK

ADDvise Group AB (publ) logo

ADDvise Group AB (publ)

ADDV-A.ST

11.6 SEK

Infant Bacterial Therapeutics AB (publ) logo

Infant Bacterial Therapeutics AB (publ)

IBT-B.ST

93.4 SEK

SpectraCure AB (publ) logo

SpectraCure AB (publ)

SPEC.ST

2.605 SEK

Xspray Pharma AB (publ) logo

Xspray Pharma AB (publ)

XSPRAY.ST

44 SEK

Orexo AB (publ) logo

Orexo AB (publ)

ORX.ST

14.5 SEK

Physitrack PLC logo

Physitrack PLC

PTRK.ST

15.2 SEK

Senzime AB (publ) logo

Senzime AB (publ)

SEZI.ST

7.25 SEK

Financiële Gegevens

Cijfers zijn in miljoenen (SEK)

Cijfers zijn in miljoenen (SEK)